Sat, Sep 20, 2014, 4:34 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Synta Pharmaceuticals Corp. (SNTA) Message Board

  • richrd_cc richrd_cc Nov 26, 2013 7:59 PM Flag

    Two stock price surges ahead

    Charts seem to point to a $6.40-$6.80 range in the short term for SNTA. An even higher surge may be realized with the upcoming ENCHANT presentation on Thursday, December 12th. I won't even guess where the price will go after that....but it could be a second surge in stock price for SNTA. The science behind heat shock protein inhibitors interruption of crucial steps to the survival of tumor progression is solid and with mechanisms of action becoming clear, ganetespib has a much higher potential for FDA approval. The key to ganetespib success is the established safety profile coupled with the efficacy data that will be coming out soon. Good luck longs....it sure looks like we are about to have a great breakout in the next few weeks and months ahead.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • We may have Enchant results on Thursday and the Harvard combo study results on Friday. We could be talking a two day surge on the catalyst date. Something to keep in mind :) If that happens we really might see 10

      • 1 Reply to ivanprokov
      • Agreed....and one of the "hidden" values of ganetespib is the combination treatment value. Ganetespib may end up being a phenomenal combination product for numerous cancers. Synergistic success may spell huge partnership value for a number of partnerships. This potential is only for the raw drug. The HDC platform products open new doors and even more partnerships. It is a very exciting time for early investors in Synta Pharmaceuticals.

        Sentiment: Strong Buy

 
SNTA
3.55-0.17(-4.57%)Sep 19 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.